More on Blastic Plasmacytoid Dendritic-Cell Neoplasms

Authors:

Abstract
To the Editor: Agha and colleagues (Oct. 11 issue)1 described a patient with a blastic plasmacytoid dendritic-cell neoplasm who received bortezomib, simvastatin, and venetoclax. The study of BCL2 inhibition in acute myeloid leukemia2 and blastic plasmacytoid dendritic-cell neoplasm3,4 has been a long-standing focus for us. We previously reported our experience with venetoclax in the latter condition, demonstrating BCL2 dependence using BH3 profiling in primary tumor cells and patient-derived xenografts, and observing major responses to venetoclax monotherapy in two elderly patients with relapsed or refractory disease.3 On the basis of these findings, we have initiated a formal phase 1 trial of . . .